Interim report
Page 1
sanofi 4th August 2026 Το The Secretary BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai 400 001 Scrip Code : 500674 The Secretary The National Stock Exchange of India Limited Exchange Plaza , C - 1 , Block G , Bandra - Kurla Complex , Bandra ( E ) Mumbai 400 051 Symbol : SANOFI Sub : Outcome of the Board Meeting of the Company Dear Sirs / Madam , We refer to our intimation dated 20th July 2026 , we hereby inform you that the Board of Directors at its meeting held today i.e. , Tuesday , 4th August 2026 , inter- alia : 1. Considered and approved the Unaudited Financial Results for the quarter and half year ended 30th June 2026 . Accordingly , we enclose a copy of the Limited Review Report , and the Unaudited Financial Results for the quarter and half year ended 30th June 2026 , as required under Regulation 33 of the SEBI ( Listing Obligations and Disclosure Requirements ) Regulations , 2015 ( " Listing Regulations " ) . A press release in this regard has also been enclosed . Extract of the aforesaid Results will be published in the newspapers in the format prescribed under Regulation 47 of the Listing Regulations . The aforesaid Financial Results will also be available on the Company's website on Financial results - Sanofi India . 2. Pursuant to Regulation 30 of the Listing Regulations , the Board of Directors have approved : a . Re - constitution of the following Committees with effect from 1st October 2026 : i . Stakeholders Relationship Committee : Sr No Name of the Member 1 Mr. Siraj Chaudhry 2 Mr. Deepak Arora 3 Ms. Sudipta Chakraborty Category Independent Director Managing Director Whole Time Director Position in the Committee Chairman Member Member Sanofi India Limited , Sanofi House , CTS No. 117 - B , L & T Business Park , Saki Vihar Road , Powai , Mumbai 400 072 - India - Tel .: +91 ( 22 ) 2803 2000 Fax : +91 ( 22 ) 2803 2939 Corporate Identity Number : L24239MH1956PLC009794 Website : www.sanofiindialtd.com | www.sanofi.in Email : igrc.sil@sanofi.com
Page 2
Sanofi India Limited, Sanofi House, CTS No. 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400 072 - India - Tel.: +91(22) 2803 2000 - Fax: +91(22) 2803 2939 Corporate Identity Number : L24239MH1956PLC009794 Website: www.sanofiindialtd.com | www.sanofi.in Email: igrc.sil@sanofi.com ii. Risk Management Committee: Sr No Name of the Member Category Position in the Committee 1 Ms. Rajani Kesari Independent Director Chairperson 2 Mr. Siraj Chaudhry Independent Director Member 3 Mr. Deepak Arora Managing Director Member 4 Mr. Mahadev Gawade Whole Time Director Member b. P ursuant to the Regulation 30(5) of the Listing Regulations, in view of stepping down of Mr. Rachid Ayari as Whole Time Director and Chief Financial Officer with effect from the close of business hours on 30th September 2026, his name wi ll be deleted from the list of Key Managerial Personnels authorised to de termine materiality of an event or information and making disclosures to the Stock Exchanges. The meeting of Board of Directors commenced at 4:00 p.m. and concluded at 6:58 p.m. Please take the above information on record. Thanking you, Yours faithfully For Sanofi India Limited ______________ Haresh Vala Company Secretary and Compliance Officer Membership No.: A18246 Encl: a/a
Page 3
Press Release Sanofi India delivers strong Q2 2026 performance, Led by double digit growth in Diabetes Portfolio and a Robust Profit Momentum Mumbai, August 4th, 2026 Sanofi India Limited announced its financial results for the quarter ended on June 30th, 2026, reporting domestic net sales growth of 8% and total net sales growth of 6% compared to the second quarter of 2025. The Insulin portfolio continued its strong trajectory, delivering double-digit growth of 14% for the second consecutive quarter, reinforcing Sanofi's leadership position in the basal analog market with a 58% value market share and 61% volume market share*. Growth was powered by Lantus®, Toujeo®, and Apidra®, alongside the successful performance of Soliqua®, the premium offering in the premix diabetes space. The public sector business accelerated by 70%, with the opening of new accounts for Toujeo® and Soliqua® under the CARE Accounts initiative, further strengthening Sanofi's footprint in the diabetes injectable space. Strategic partnerships in Cardiovascular, Oral anti -Diabetes and Central Nervous System segments have established a strong foundation, meeting expectations for market reach expansion. Partnership revenues grew 2% in Q2 2026, with continued return on investment from an expanded commercial footprint Export sales remained broadly stable, demonstrating the resilience of Sanofi India's international operations amid global headwinds. Profits before tax and exceptional items increased 19% to INR 112 crores , compared to INR 94 crores in the second quarter 2025. Profit before tax as a percentage of net sales improved to 27% in Q2 2026, up from 24% in Q2 2025. This improvement reflects a favorable product mix and disciplined cost management through operational efficiencies, with operating expenses (employee cost + other expenses) declining 5% compared to the second quarter of 2025.
Page 4
Deepak Arora Managing Director "Q2 2026 marks another chapter of purposeful, profitable growth for Sanofi India, with our diabetes portfolio posting double -digit growth for the second consecutive quarter and profit before tax growing 19%. These results reflect the discipline and momentum we have built across the business. Our acceleration in the public sector demonstrates that we are not just growing; we are broadening access to innovative therapies across the country. With a 57.3% value share in the diabetes injectable segment, a moderni zed go-to-market model, and a business that has grown 17% in the first half of 2026, the foundation for sustainable, long -term value creation is firmly in place. As we mark seven decades of serving Indian patients, guided by our purpose to chase the miracles of science, we remain focused on capturing the immense growth opportunity that India's diabetes landscape presents." * Source for market share: IQVIA MAT June 2026 Sanofi in India Present in India for nearly seven decades, Sanofi has earned the trust of customers and stakeholders for its commitment to promoting health. As Sanofi chases the miracles of science to improve people’s lives, it continues to engage across the entire health spectrum from prevention with vaccines to wellness, treatment, patient support & capacity building. Sanofi’s India Charitable Access Program (InCAP) is the country’s longest running humanitarian program providing free treatment to people afflicted with Lysosomal Storage Disorders. Sanofi conducts clinical trials in India, so that the country can have quicker access to the latest from the company’s global pipeline. Sanofi India’s world-class manufacturing site in Goa produces for people in India and 24+ other countries. Sanofi has located one of its global talent hubs in Hyderabad, India, from where wide range of services are provided globally. Recognized by the ‘Top® Employers Institute’ – a global authority that honours excellence in people practices from 2019-2024, Sanofi’s local entities include Sanofi India Limited (SIL - listed entity), and Sanofi Healthcare India Pvt. Ltd. (SHIPL). For more information, visit: www.sanofi.com/en/india, LinkedIn and X. Media Relations Vinifer Gandhi | vinifer.gandhi@sanofi.com
Page 5
Price Waterhouse & Co Chartered Accountants LLP Price Waterhouse & Co Chartered Accountants LLP, Nesco IT Building III, 8th Floor, Nesco IT Park, Nesco Complex Gate No. 3 Western Express Highway, Goregaon East, Mumbai 400 063 T: +91 (22) 61197808 Registered office and Head office: Plot No. 56 & 57, Block ON, Sector-V, Salt Lake, Kolkata - 700 091 Price Waterhouse & Co. (a Partnership Firm) converted into Price Waterhouse & Co Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-4362) with effect from July 7, 2014. Post its conversion to Price Waterhouse & Co Chartered Accountants LLP, its ICAI registration number is 304026E/E300009 (ICAI registration number before conversion was 304026E) Review Report To The Board of Directors Sanofi India Limited CTS No. 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400 072 1. We have reviewed the unaudited financial results of Sanofi India Limited (the “Company”) for the quarter ended June 30, 2026 and the year to date results for the period January 01, 2026 to June 30, 2026, the Unaudited Statement of Assets and Liabilities as on that date and the Unaudited Statement of Cash Flows for the half-year ended on that date which are included in the accompanying ‘Statement of Unaudited Financial Results for the quarter and half year ended June 30, 2026’ (the “Statement”). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations, 2015”), which has been digitally signed by us for identification purposes. The Statement is the responsibility of the Company’s Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review. 2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. 3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion. 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement. For Price Waterhouse & Co Chartered Accountants LLP Firm Registration Number: 304026E/E-300009 Arunkumar Ramdas Partner Membership Number: 112433 UDIN: 26112433VMUERB4705 Place: Mumbai Date: August 04, 2026
Page 6
₹ in Million Quarter Quarter Quarter Half year Half year Year ended ended ended ended ended ended 30.06.2026 31.03.2026 30.06.2025 30.06.2026 30.06.2025 31.12.2025 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) 1. Revenue from Operations 4,377 4,723 4,063 9,100 9,422 18,374 2. Other Income 62 44 87 106 120 197 3. Total Income (1+2) 4,439 4,767 4,150 9,206 9,542 18,571 4. Expenses (a) Cost of Materials Consumed 573 503 621 1,076 1,378 2,464 (b) Purchases of stock-in-trade 1,589 1,482 356 3,071 1,197 5,140 (c) Changes in Inventories of work-in-progress, stock-in-trade and finished goods 90 358 1,110 448 1,917 1,368 (d) Employee benefits expense 446 428 449 874 987 1,853 (e) Finance costs 3 3 4 6 7 17 (f) Depreciation and amortisation expense 89 90 91 179 187 373 (g) Other expenses 526 524 578 1,050 1,275 2,636 Total Expenses 3,316 3,388 3,209 6,704 6,948 13,851 5. Profit before exceptional item and tax (3-4) 1,123 1,379 941 2,502 2,594 4,720 6. Exceptional item (Refer note 3) - - - - - (273) 7. Profit before tax (5+6) 1,123 1,379 941 2,502 2,594 4,447 8. Income tax expense Current Tax 297 343 250 640 707 1,229 Deferred Tax (9) 10 (4) 1 (3) (49) 9. Profit for the period /year (7-8) 835 1,026 695 1,861 1,890 3,267 10. Other comprehensive income (OCI) (Net of Tax) - - - - - 17 11. Total comprehensive income for the period/year (9+10) 835 1,026 695 1,861 1,890 3,284 12. Paid-up equity share capital (Face Value of ₹ 10 per share) 230 230 230 230 230 230 13. Other equity - - - - - 7,262 14. Basic and diluted earnings per share (not annualised) (in ₹) 36.26 44.55 30.18 80.81 82.07 141.85 The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the review report dated August 04, 2026 Particulars STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED JUNE 30, 2026 SANOFI INDIA LIMITED Registered Office : Sanofi House,C.T.S No - 117-B, L & T Business Park, Saki Vihar Road, Powai, Mumbai 400 072. Corporate Identity Number: L24239MH1956PLC009794 Tel no: (91-22) 28032000 Fax No: (91-22) 28032846 Website: www.sanofiindialtd.com Email: igrc.sil@sanofi.com
Page 7
SANOFI INDIA LIMITED UNAUDITED STATEMENT OF ASSETS AND LIABILITIES ₹ in Million As at June 30, 2026 As at December 31, 2025 Unaudited Audited ASSETS Non-current assets Property, plant and equipment 2,392 2,493 Capital work in progress 192 116 Right-of-use assets 508 541 Intangible assets 7 7 Financial assets Other financial assets 88 68 Income tax assets (net) 1,159 1,212 Deferred tax assets (net) 43 44 Other non-current Assets 35 61 Total non-current assets 4,424 4,542 Current Assets Inventories 3,112 3,116 Financial assets (i) Trade receivables 2,321 1,767 (ii) Cash and cash equivalents 3,590 2,629 (iii) Bank Balances other than (ii) above 97 120 (iv) Loans 3 9 (v) Other financial Assets 53 28 Other current assets 474 337 Total current assets 9,650 8,006 TOTAL ASSETS 14,074 12,548 EQUITY AND LIABILITIES Equity Equity share capital 230 230 Other equity Reserves and surplus 8,030 7,262 Total equity 8,260 7,492 LIABILITIES Non-current liabilities Financial liabilities Lease liabilities 108 137 Provisions - employee benefit obligations 5 5 Total non-current liabilities 113 142 Current liabilities Financial liabilities (i) Lease liabilities 39 41 (ii) Trade payables (a) Total outstanding dues of micro enterprises and small enterprises 87 100 (b) Total outstanding dues of creditors other than micro enterprises and small enterprises 2,653 1,840 (iii) Other financial liabilities 485 610 Provisions - others 1,075 1,135 Provisions - employee benefit obligations 250 198 Current tax liabilities (net) 1,091 957 Other current liabilities 21 33 0 Total current liabilities 5,701 4,914 Total liabilities 5,814 5,056 TOTAL EQUITY AND LIABILITIES 14,074 12,548 The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the review report dated August 04, 2026 Particulars
Page 8
04-08-2026 14:16 SANOFI INDIA LIMITED 0 (0) UNAUDITED STATEMENT OF CASH FLOWS FOR THE HALF YEAR ENDED JUNE 30, 2026 ₹ in Million Profit before tax 2,502 2,594 Adjustment for : Depreciation and amortisation expenses 179 187 Unrealised exchange loss / (gain) (net) 4 (4) (5) (1) (Gain) on termination/retirement of lease (net) * (11) Finance costs 6 7 Interest income (78) (68) Share based payment (net) 12 19 Provision for bad and doubtful debts (net) (6) 11 Provision for doubtful advances and deposits (net) (6) - Operating profit before working capital changes 2,608 2,734 Adjustments for (increase) / decrease in operating assets Non-current financial assets (14) 6 Other non-current assets * * Inventories 4 2,281 Trade receivables (558) 698 Current financial assets, loans and other bank balances 4 392 Other current assets (137) 219 Adjustments for increase / (decrease) in operating liabilities Provisions - employee benefit obligations 52 (9) Trade payables 806 (2,640) Current financial liabilities (126) (213) Other current liabilities, loans and provisions - others (72) (130) Cash generated from operations 2,567 3,338 Taxes paid (Net of refunds) (453) (428) Net Cash inflow from operating activities (A) 2,114 2,910 Cash flow from Investing activities Sale proceeds of property, plant and equipment 9 5 Interest received 78 68 Purchase of property, plant and equipment and Intangible assets including Capital work-in-progress (110) (144) Net cash outflow from investing activities (B) (23) (71) Cash flow from financing activities Principal elements of lease payments (19) (24) Interest paid (6) (7) Dividend paid (1,105) (2,695) Net cash outflow from financing activities (C) (1,130) (2,726) Net increase in cash and cash equivalents (A+B+C) 961 113 * * Cash and Cash Equivalents at the beginning of the period 2,629 2,838 Cash and Cash Equivalents at the end of the period 3,590 2,951 Non- cash financing and investing activities (D) Acquisition of Right-of-use assets - 131 Components of Cash and Cash Equivalents Cash and Cash Equivalents 3,590 2,951 * denotes figure less than a million. The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the review report dated August 04, 2026 Effect of Exchange differences on cash and cash equivalents held in foreign currency Particulars Half year ended June 30, 2026 (Unaudited) Half year ended June 30, 2025 (Unaudited) Cash flow from operating activities (Gain) on sale of property, plant and equipment
Page 9
Notes: 1. The above Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on August 04, 2026. The statutory auditors have carried out a limited review of the above results for the quarter and half year ended June 30, 2026. 2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable. 3. Exceptional items relate to personnel separation costs of ₹273 million for the year ended December 31, 2025. 4. The Company has a single business segment namely ‘Pharmaceutical Business’. SANOFI INDIA LIMITED The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the review report dated August 04, 2026 DEEPAK ARORA MANAGING DIRECTOR DIN: 07495638 August 04, 2026